Estudio de tratamiento neoadyuvante en cáncer de mama con esquema de densidad de dosis: adriamicina¿ciclofosfamida seguidos de docetaxel junto trastuzumab sobreexpresión de Her¿2
Study of neoadjuvant treatment in breast cancer with dose dense regime: adriamycin-cyclophosphamide followed by docetaxel together with trastuzumab overexpressing of Her-2
Leído
14396
Vecesse ha leído el artículo
1316
Total PDF
13080
Total HTML
Información del artículo
ISSN: 22536450Idioma original: Español
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 29 | 5 | 34 |
| 2025 11 | 127 | 32 | 159 |
| 2025 10 | 103 | 13 | 116 |
| 2025 9 | 123 | 22 | 145 |
| 2025 8 | 162 | 14 | 176 |
| 2025 7 | 162 | 18 | 180 |
| 2025 6 | 162 | 4 | 166 |
| 2025 5 | 138 | 7 | 145 |
| 2025 4 | 152 | 5 | 157 |
| 2025 3 | 183 | 6 | 189 |
| 2025 2 | 171 | 5 | 176 |
| 2025 1 | 234 | 7 | 241 |
| 2024 12 | 189 | 11 | 200 |
| 2024 11 | 157 | 8 | 165 |
| 2024 10 | 160 | 2 | 162 |
| 2024 9 | 197 | 11 | 208 |
| 2024 8 | 185 | 7 | 192 |
| 2024 7 | 189 | 11 | 200 |
| 2024 6 | 169 | 10 | 179 |
| 2024 5 | 144 | 14 | 158 |
| 2024 4 | 190 | 13 | 203 |
| 2024 3 | 142 | 11 | 153 |
| 2024 2 | 166 | 19 | 185 |
| 2024 1 | 195 | 9 | 204 |
| 2023 12 | 170 | 11 | 181 |
| 2023 11 | 457 | 15 | 472 |
| 2023 10 | 213 | 8 | 221 |
| 2023 9 | 186 | 4 | 190 |
| 2023 8 | 131 | 9 | 140 |
| 2023 7 | 151 | 8 | 159 |
| 2023 6 | 144 | 8 | 152 |
| 2023 5 | 217 | 19 | 236 |
| 2023 4 | 137 | 12 | 149 |
| 2023 3 | 201 | 17 | 218 |
| 2023 2 | 101 | 8 | 109 |
| 2022 1 | 120 | 10 | 130 |
| 2022 12 | 107 | 7 | 114 |
| 2022 11 | 179 | 15 | 194 |
| 2022 10 | 156 | 23 | 179 |
| 2022 9 | 118 | 20 | 138 |
| 2022 8 | 149 | 28 | 177 |
| 2022 7 | 88 | 19 | 107 |
| 2022 6 | 111 | 15 | 126 |
| 2022 5 | 123 | 15 | 138 |
| 2022 4 | 101 | 22 | 123 |
| 2022 3 | 136 | 22 | 158 |
| 2022 2 | 136 | 8 | 144 |
| 2021 1 | 165 | 19 | 184 |
| 2021 12 | 112 | 18 | 130 |
| 2021 11 | 144 | 15 | 159 |
| 2021 10 | 146 | 22 | 168 |
| 2021 9 | 128 | 12 | 140 |
| 2021 8 | 134 | 14 | 148 |
| 2021 7 | 320 | 11 | 331 |
| 2021 6 | 134 | 18 | 152 |
| 2021 5 | 163 | 7 | 170 |
| 2021 4 | 346 | 20 | 366 |
| 2021 3 | 243 | 17 | 260 |
| 2021 2 | 167 | 22 | 189 |
| 2020 1 | 195 | 21 | 216 |
| 2020 12 | 174 | 21 | 195 |
| 2020 11 | 147 | 16 | 163 |
| 2020 10 | 88 | 11 | 99 |
| 2020 9 | 103 | 12 | 115 |
| 2020 8 | 129 | 17 | 146 |
| 2020 7 | 123 | 13 | 136 |
| 2020 6 | 120 | 10 | 130 |
| 2020 5 | 145 | 11 | 156 |
| 2020 4 | 170 | 10 | 180 |
| 2020 3 | 153 | 17 | 170 |
| 2020 2 | 153 | 7 | 160 |
| 2020 1 | 104 | 9 | 113 |
| 2019 12 | 110 | 22 | 132 |
| 2019 11 | 53 | 10 | 63 |
| 2019 10 | 75 | 11 | 86 |
| 2019 9 | 80 | 22 | 102 |
| 2019 8 | 90 | 4 | 94 |
| 2019 7 | 50 | 6 | 56 |
| 2019 6 | 103 | 32 | 135 |
| 2019 5 | 163 | 27 | 190 |
| 2019 4 | 122 | 20 | 142 |
| 2019 3 | 45 | 5 | 50 |
| 2019 2 | 43 | 13 | 56 |
| 2019 1 | 31 | 3 | 34 |
| 2018 12 | 24 | 2 | 26 |
| 2018 11 | 35 | 11 | 46 |
| 2018 10 | 54 | 11 | 65 |
| 2018 9 | 32 | 7 | 39 |
| 2018 8 | 12 | 3 | 15 |
| 2018 7 | 20 | 6 | 26 |
| 2018 6 | 24 | 5 | 29 |
| 2018 5 | 32 | 8 | 40 |
| 2018 4 | 28 | 1 | 29 |
| 2018 3 | 19 | 1 | 20 |
| 2018 2 | 19 | 2 | 21 |
| 2018 1 | 11 | 0 | 11 |
| 2017 12 | 19 | 2 | 21 |
| 2017 11 | 13 | 3 | 16 |
| 2017 10 | 20 | 2 | 22 |
| 2017 9 | 21 | 10 | 31 |
| 2017 8 | 17 | 2 | 19 |
| 2017 7 | 10 | 5 | 15 |
| 2017 6 | 19 | 13 | 32 |
| 2017 5 | 18 | 13 | 31 |
| 2017 4 | 10 | 0 | 10 |
| 2017 3 | 19 | 26 | 45 |
| 2017 2 | 13 | 4 | 17 |
| 2016 1 | 3 | 2 | 5 |
| 2016 12 | 23 | 8 | 31 |
| 2016 11 | 22 | 12 | 34 |
| 2016 10 | 33 | 12 | 45 |
| 2016 9 | 35 | 3 | 38 |
| 2016 8 | 30 | 5 | 35 |
| 2016 7 | 13 | 5 | 18 |
Mostrar todo